Literature DB >> 30918339

Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL.

Libing Wang1, Juan Du2, Aijie Huang1, Gusheng Tang1, Shenglan Gong1, Hui Cheng1, Weiping Zhang1, Jianmin Yang1, Jianmin Wang1, Xiaoxia Hu3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30918339     DOI： 10.1038/s41409-019-0514-4

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Authors:  S Nishiwaki; K Imai; S Mizuta; H Kanamori; K Ohashi; T Fukuda; Y Onishi; S Takahashi; N Uchida; T Eto; H Nakamae; T Yujiri; S Mori; T Nagamura-Inoue; R Suzuki; Y Atsuta; J Tanaka
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

2.  Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission.

Authors:  W-Z Cai; J-N Cen; J Chen; F Chen; C-C Fu; Y Han; Z-M Jin; X Ma; M Miao; H-Y Qiu; X-W Tang; S-L Xue; A-N Sun; S-N Chen; D-P Wu
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

3.  Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.

Authors:  Federico Lussana; Tamara Intermesoli; Francesca Gianni; Cristina Boschini; Arianna Masciulli; Orietta Spinelli; Elena Oldani; Manuela Tosi; Anna Grassi; Margherita Parolini; Ernesta Audisio; Chiara Cattaneo; Roberto Raimondi; Emanuele Angelucci; Irene Maria Cavattoni; Anna Maria Scattolin; Agostino Cortelezzi; Francesco Mannelli; Fabio Ciceri; Daniele Mattei; Erika Borlenghi; Elisabetta Terruzzi; Claudio Romani; Renato Bassan; Alessandro Rambaldi
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-01       Impact factor: 5.742

4.  Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Authors:  C Eckert; N Hagedorn; L Sramkova; G Mann; R Panzer-Grümayer; C Peters; J-P Bourquin; T Klingebiel; A Borkhardt; G Cario; J Alten; G Escherich; K Astrahantseff; K Seeger; G Henze; A von Stackelberg
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

5.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

6.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Nicholas J Short; Elias Jabbour; Koji Sasaki; Keyur Patel; Susan M O'Brien; Jorge E Cortes; Rebecca Garris; Ghayas C Issa; Guillermo Garcia-Manero; Rajyalakshmi Luthra; Deborah Thomas; Hagop Kantarjian; Farhad Ravandi
Journal:  Blood       Date:  2016-05-27       Impact factor: 22.113

7.  Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

Authors:  Renato Bassan; Giuseppe Rossi; Enrico M Pogliani; Eros Di Bona; Emanuele Angelucci; Irene Cavattoni; Giorgio Lambertenghi-Deliliers; Francesco Mannelli; Alessandro Levis; Fabio Ciceri; Daniele Mattei; Erika Borlenghi; Elisabetta Terruzzi; Carlo Borghero; Claudio Romani; Orietta Spinelli; Manuela Tosi; Elena Oldani; Tamara Intermesoli; Alessandro Rambaldi
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

8.  Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jeffrey L Jorgensen; Elias Jabbour; Nitin Jain; Deborah Thomas; Susan O'Brien; Xuemei Wang; Xuelin Huang; Sa A Wang; Marina Konopleva; Sergej Konoplev; Tapan Kadia; Rebecca Garris; Sherry Pierce; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2017-02-01       Impact factor: 10.047

9.  Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden.

Authors:  Wei-Ping Zhang; Dan Yang; Xian-Min Song; Xiong Ni; Jie Chen; Li Chen; Jian-min Yang; Hong Zhou; Hui Cheng; Bao-Hai Liu; Hong-Mei Li; Jian-Min Wang
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-22       Impact factor: 5.742

10.  A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Authors:  Sabina Chiaretti; Antonella Vitale; Marco Vignetti; Alfonso Piciocchi; Paola Fazi; Loredana Elia; Brunangelo Falini; Francesca Ronco; Felicetto Ferrara; Paolo De Fabritiis; Mario Luppi; Giorgio La Nasa; Alessandra Tedeschi; Catello Califano; Renato Fanin; Fausto Dore; Franco Mandelli; Giovanna Meloni; Robin Foà
Journal:  Haematologica       Date:  2016-08-11       Impact factor: 9.941
View more
  2 in total

1.  Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Qiang Zeng; Bing Xiang; Zhigang Liu
Journal:  Cancer Med       Date:  2021-11-11       Impact factor: 4.452

Review 2.  Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

Authors:  Kyaw Hein; Nicholas Short; Elias Jabbour; Musa Yilmaz
Journal:  Blood Lymphat Cancer       Date:  2022-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.